dilmapimod

Dilmapimod is a small molecule inhibitor of p38 mitogen-activated protein kinase (MAPK), specifically targeting the p38α isoform. It was developed for its anti-inflammatory properties and has been investigated in clinical trials for several inflammatory and pain-related conditions, including rheumatoid arthritis, neuropathic pain, nerve trauma, coronary artery disease, acute lung injury, adult respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and atherosclerosis. Dilmapimod acts by reducing levels of proinflammatory cytokines such as TNFα, IL-1β, and IL-6 through inhibition of p38 MAPK signaling pathways. This results in decreased cellular infiltration at sites of inflammation and reduced local tissue damage. Despite promising early-phase results showing tolerability and biomarker modulation in patients at risk for ARDS or with neuropathic pain, development was discontinued after phase II/III trials due to lack of sufficient efficacy or strategic reasons[1][2][4][5][8].

Other names

dilmapimod tosylate